Sorafenib in advanced hepatocellular carcinoma [3]

New England Journal of Medicine

Volumn 359, Issue 23, 2008, Pages 2498-

  Copur, Mehmet S ^a  

^a Saint Francis Medical Center Grand Island   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB; BENZENESULFONIC ACID DERIVATIVE; BIOLOGICAL MARKER; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADVANCED CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE ASSOCIATION; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FUNCTION; PRIORITY JOURNAL; TREATMENT RESPONSE; BLOOD; DISEASE COURSE; LIVER TUMOR; NOTE; SURVIVAL RATE;

ALPHA-FETOPROTEINS; BENZENESULFONATES; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HUMANS; LIVER NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; SURVIVAL RATE;

EID: 57349191046     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001;5:145-59.
2. Huo TI, Huang YH, Lui WY, et al. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. Oncol Rep 2004;11:543-50.
3. Díaz Sánchez A, Núñez Martinez O, Prieto Martin M, et al. Prognostic factors in patients with non-active treatment of hepatocellular carcinoma. Gastroenterol Hepatol 2007;30:441-8.